Skip to main content

By Biocat

The Daniel Bravo-Andreu Foundation has launched the first call for proposals for two grants for 3- to 6-month stays so that Catalan researchers can collaborate in cardiovascular research projects and groups at prestigious American and European centers. Applications can be submitted from 15 May to 15 June 2013.

Cardiovascular diseases are the leading cause of death around the world. The most common is myocardial ischemia, which has numerous long-term after effects. In Europe and the United States alone, 1.5 million acute myocardial infarctions are treated each year. Treating these diseases is one of the key challenges facing healthcare systems in developed countries, and more and more in developing countries as well, as 30 international experts concluded during their participation in the scientific debate organized by B·Debate and the Vall d'Hebron Research Institute (VHIR) last November in Barcelona.

To be eligible for these grants, scientists must meet the following criteria:

  • Have a university degree.
  • Belong to the teaching or research staff at one of the universities, research centers or hospital foundations in the Catalan research system.
  • Live in Catalonia at the time of application.
  • Speak the language of the destination country and have a high level of spoken and written English.

The destination centers (hospitals, universities and research institutes) may be chosen freely by Catalan researchers applying for these grants. Each grant will have a stipend of €3,000 gross per month plus travel expenses, which must be approved by the Foundation.

In selecting the grant winners, who will be announced on 15 July, the Bravo-Andreu Foundation will take into account the scientific quality of the applicant, the project and the institution where the research will be carried out.

Rules and regulations and application form

Questions: beques@fundaciodanielbravo.org

Tags:
Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.